- LOGIN
- MemberShip
- 2025-12-27 03:47:02
- Company
- Nicetile's Rx has decreased by 40% over the past year
- by Chon, Seung-Hyun Jul 02, 2020 06:08am
- Sales of 'Acetyl-L-Carnitine (ALC)', a brain function improving agent, fell sharply. As a result of clinical re-evaluation, the market size has decreased by 40% in one year as indications have been reduced. The market for 'Choline alfoscerate', which is predicted for clinical re-evaluation, is also expected to change depending on the results. According to UBIST, a pharmaceutical research institute on the 28th, the outpatient prescription amount of ALC in the first quarter was ₩11.7 billion, a 37.9% decrease from the same period last year. Dong-A ST's ALC, generic for Nicetile, is approved for use in 'primary degenerative diseases' or 'secondary degenerative diseases caused by cerebrovascular diseases'. However, as a result of the clinical reevaluation ordered by the MFDS in 2015, the indication was deleted in July as it was unable to prove the efficacy of the 'primary degenerative disease'. Quarterly Rx amounts of ALC (Unit: ₩1 million, Source: UBIST) Acetyl-L-Carnitine (ALC) formulations have steadily formed a market size of nearly ₩20 billion every quarter. In the first quarter and the second quarter of last year, the prescription results were ₩18.9 billion and ₩17.9 billion respectively. However, the scale of prescriptions has dropped significantly since the reduction of indications. In the third quarter of last year, it fell 26.8% from the previous year to ₩13.5 billion, and in the fourth quarter of last year, it decreased by 38.0% compared to the previous year to ₩12.1 billion. This year, This trend has accelerated. It is analyzed that the prescription avoidance phenomenon has spread due to the reduction in indications according to the reevaluation results. The market for ALC products has been slower since the recent spread of COVID-19. In April and May last year, the prescription amounts of ALC were recorded at ₩6.5 billion and ₩6.4 billion, respectively. The ALC based products had a large reduction in prescription sales amount. Major ALC outpatients prescription amount (Unit: ₩ 1 million, %, Source: UBIST) Hanmi's 'Carnitil', which is currently in the top position in the market, has a 32.8% decrease in prescription performance in the first quarter to ₩3.7 billion. Dong-A ST's 'Nicetile ' decreased 29.4% from ₩2.7 billion in the first quarter of last year to ₩1.9 billion in the first quarter of this year. Daewoong Bio, Samik, and Myungmoon, all of which have the highest prescriptions, have significantly reduced their prescription amounts from last year. As a result of re-evaluation of the Choline alfoscerate, which has recently been decided on a clinical re-evaluation policy, such as Acetyl-L-Carnitine, it is predicted that prescription reduction will be inevitable if some indications are deleted. Choline alfoscerate is a drug that has three indications: ▲secondary symptoms due to cerebrovascular defects and degenerative or degenerative cerebral stromal psychological syndrome ▲emotional and behavioral changes ▲senile pseudoplastic depression. It recorded a total of ₩352.5 billion in prescriptions last year, and has established itself as a new source of revenue for pharmaceutical companies. The MFDS approved an item renewal for Choline alfoscerate in 2018, but announced that it would conduct a clinical re-evaluation of Choline alfoscerate on the 23rd as the efficacy controversy continued. The MFDS ordered 255 items from 134 companies to submit domestic clinical trial results. When conducting a clinical trial, it was instructed to submit IND by December 23.
- Company
- European license for Avastin biosimilar is imminent.
- by Chon, Seung-Hyun Jul 01, 2020 05:55am
- Samsungbioepis Samsung Bioepis said on the 28th (local time) that it received a positive opinion on the approval of ‘Avastin biosimilar, Aybintio' from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). It received positive feedback from the CHMP about 11 months after the launch of EMA's marketing authorization review in July last year. As a result, Samsung Bioepis expected that it would be able to obtain an official sales license after a final review by the European Commission (EC), which usually takes 2-3 months. Avastin, the original for Aybintio, is a treatment for tumor diseases sold by Roche, Switzerland. In Europe, it has indications such as metastatic colorectal cancer, non-small cell lung cancer, and metastatic breast cancer. Avastin's global market sales last year amounted to about ₩8.5 trillion, of which Europe accounts for about a quarter. Amgen’s and Pfizer’s Avastin biosimilars are currently licensed by the United States and Europe. Among Korean companies, Celltrion is conducting Phase III clinical trials of Avastin Biosimilar. Samsung Bioepis announced the results of Phase III clinical trials of Aybintio at the regular conference of the European Society for Medical Oncology in Barcelona, Spain last September. Aybintio proved the equivalence of risk ratio of best ORR2 to the original drug through a study of a total of 763 non-small cell lung cancer patients. Aybintio is the fifth biosimilar product from Samsung Bioepis. In November of last year, the U.S. Food and Drug Administration (FDA) launched an approval test. Samsung Bioepis currently treats anti-cancer drugs such as 'Benepali' (Enbrel biosimilar), 'Imraldi' (Humira biosimilar), 'Flixabi' (Remicade biosimilar), and ‘Ontruzant' (Herceptin biosimilar) in Europe. "The company's R&D capability has been proven once again, and it has opened up the possibility of further expanding the treatment benefits of cancer patients through high-quality biopharmaceuticals," said Koh Seung-han, president of Samsung Bioepis.
- Company
- Complaint against the plan to reduce benefits of α-GPC
- by Chon, Seung-Hyun Jun 30, 2020 06:11am
- Pharmaceutical companies agreed to file a complaint against the government's plan to reduce the reimbursement of Choline alfoscerate. It is suggested that the co-payment rate be lowered for reasons such as high cognitive impairment and brain-related diseases with high prescription rates. According to the industry on the 29th, more than 100 executives from pharmaceutical companies with Choline alfoscerate had an emergency meeting on that day and sought a response strategy to the government's policy to reduce the benefit. Gliatamin byDaewoong Bio & Gliatilin by Chong Kun Dang At the meeting, which was conducted by online video conference, it was agreed that an appeal would be needed to reduce the coverage of Choline alfoscerate. The HIRA held the Pharmaceutical Benefits Advisory Committee on the 11th to deliberate the appropriateness of the choline alfoscerate formulation, and then decided positive list system according to efficacy and effectiveness. Choline alfoscerate is a drug that has three indications: ▲secondary symptoms and degenerative or degenerative cerebral stromal psychological syndrome ▲emotional and behavioral changes ▲senile pseudodepression. When a patient diagnosed with dementia uses this drug for the purpose of improving symptoms such as cognitive impairment, the copayment rate of 30% is maintained as before. However, dementia patients only pay 10% copayment. However, if a patient who has not been diagnosed with dementia is prescribed a Choline alfoscerate product, it increases from 30% to 80%. The prescription performance of choline alfoscerate last year was ₩352.5 billion. Among them, the diagnosis of dementia patients whose benefits are maintained as in the past was only ₩60 billion, only 17% of the total. More than 80% of the prescriptions for Choline alfoscerate drugs increase the patient's drug burden by 2.7%. Pharmaceutical companies shared a strategy to lead to a downward adjustment of the co-payment rate through appeals against areas where the drug cost burden rate will increase to 80%. To this end, it was reported that each area discussed the need for a response strategy that provides a basis for refuting the health authorities' decision. In the near future, the HIRA will notify pharmaceutical companies of the conversion of Choline alfoscerate formulations to a positive list system determined by the Pharmaceutical Benefits Advisory Committee. In response, pharmaceutical companies can appeal only once. In addition to dementia for which an increase in the co-payment rate has been announced, the strategy of pharmaceutical companies is to actively lead to a downward adjustment of the co-payment rate in the areas of mild cognitive impairment and other brain-related diseases in 'Secondary symptoms and degenerative or degenerative brain-based psychotic syndrome due to cerebrovascular defects'. The health authorities decided to re-evaluate the Choline alfoscerate product, taking into account its clinical usefulness, cost effectiveness, and social needs. However, pharmaceutical companies believe that in the case of mild cognitive impairment and other brain-related diseases, the 30% of copayment should be applied or lowered to 50%. There are not many drugs to replace for mild cognitive impairment and brain-related diseases of Choline alfoscerate and they said that it is unfair to increase the copayment rate under high social demand. In the case of mild cognitive impairment and brain-related diseases, which are serious diseases, it has been reported that despite the clinical usefulness, patients may be deprived of treatment opportunities if their drug burden increases. Pharmaceutical companies believe that mild cognitive impairment may increase the risk of dementia in the future, so treatment through drug administration is important. Studies have been reported that Choline alfoscerate is effective in mild cognitive impairment and brain-related disorders, but it has been reported that it has not been reflected in the re-evaluation of reimbursement. Last year, in mild cognitive impairment and other brain-related diseases, Choline alfoscerate formulations showed prescription performances of ₩252.8 billion, more than 70% of the total prescription amount. The pharmaceutical company believes that the positive list system of Choline alfoscerate formulations is confirmed, which can lead to a reduction in prescriptions if the patient's drug burden increases. The meeting did not discuss the clinical re-evaluation of Choline alfoscerate formulation recently announced by the MFDS. On the 23rd, the MFDS ordered 255 items from 134 companies to submit domestic clinical trial results. It was instructed to submit a clinical trial plan by December 23 if a clinical trial is conducted.
- Company
- Spravato, a nasal spray for TRD entered the domestic market
- by Eo, Yun-Ho Jun 30, 2020 06:09am
- Spravato is the first nasal spray medication, taken along with an oral antidepressant, for adults with treatment-resistant depression (TRD) and it enters the domestic market. According to the related industry, Janssen’s Spravato nazal spray (Esketamine HCl) as a treatment for moderate to severe major depressive disorder (treatment-resistant depression) in adults who do not adequately respond to at least two different oral antidepressants from the MFDS on the 23rd has been approved for oral antidepressant use in combination. Treatment-resistant depression refers to a case in which patients who are currently suffering from major depressive disorder (MDD) have taken two or more other antidepressants at appropriate doses for a sufficient period of time, but do not improve their symptoms due to inadequate response. In general, it is estimated that about one-third of patients with depressive disorder correspond to treatment-resistant depression. Spravato is a new mechanism of nasal spray treatment that first appeared in the field of treatment-resistant depression and 30 years in the major depressive disorder. The main component of Spravato, Esketamine, improves the symptoms of depression by regulating the activity of glutamic acid receptors called NMDA receptors in the brain to restore synaptic connections and increase neurotrophic signaling. The efficacy of the drug has been demonstrated in a phase III clinical trial consisting of short-term and long-term clinical trials in more than 1700 adult patients with treatment-resistant depression. In a short-term clinical trial of treatment-resistant depression between 18 and under 65 years of age, the combined group of patients with Spravato and oral antidepressants showed a decrease of 19.8 points on the Montgomery-Asberg Depression Assessment Scale (MADRS) over a 4-week treatment period. On the other hand, the group of patients receiving placebo and oral antidepressants in combination showed a decrease of 15.8 points, and statistically, it was confirmed that the symptoms of the group of patients receiving combination of Spravato and oral antidepressants were improved. In a long-term clinical study, patients who had stable remission by using Spravato and oral antidepressants were found to have a 51% reduction in the likelihood of recurrence of depressive symptoms compared to those who received placebo and oral antidepressants. Deok-in Jeon, Chairman of the Korean Society for Affective Disorders, said, "Resistant depression, which has a longer duration of disease and more severe symptoms than normal depression, causes serious pain to patients and their caregivers. Approval of Spravato is an innovative treatment option for new mechanisms in the field of depression that have not had new drugs in the past decades."
- Company
- Prevymis by MSD is noted whether it is listed
- by Eo, Yun-Ho Jun 29, 2020 06:13am
- It is noteworthy whether the coverage for prevention of cytomegalovirus, infection in allogeneic hematopoietic stem cell transplant patients will be expanded. According to related industries, 'Prevymis (Letermovir)', a preventive treatment for cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients, which passed the Pharmaceutical Benefits Advisory Committee of the HIRA last month, will enter into drug price negotiations with the NHIS. It is interpreted that the evaluation of the adequacy of Prevymis is clinically useful and cost effective compared to the case which is not prevented. This is similar to the government's policy to strengthen health insurance coverage. Allogeneic hematopoietic stem cell transplantation is essential for the treatment of severe hematologic cancer patients such as acute myelogenous leukemia and acute lymphocytic leukemia The government has increased the age limit for the payment of hematopoietic stem cell transplants from under 65 to under 70 in 2019 as a policy to strengthen health insurance coverage. Efforts have been made to revitalize transplants and reduce costs, including recognizing primary allograft as a nursing care benefit. When cytomegalovirus (CMV) is reactivated in patients with hematopoietic stem cell transplantation, diseases such as pneumonia, hepatitis, myocarditis, gastroenteritis, and encephalitis develop. Even if the level of CMV is low, it has an effect on mortality. In the case of hematopoietic stem cell transplantation patients with CMV infection, there is a report that the mortality rate during initial hospitalization is 3.5 times higher than that of non-infected patients, and the risk of death is 2.6 times higher in patients with CMV viremia at the early stage of transplantation (within 60 days). However, CMV treatment in allogeneic hematopoietic stem cell transplantation patients is currently relying on pre-emptive administration of antiviral agents when the concentration of virus in the blood exceeds a certain level. Sung-Soo Yoon (SNU), Chairman of the Korean Society of Hematology said, "The limitations of current preemptive treatments that can only be started after the CMV blood level reaches the threshold are clear. In particular, the demand for treatment sites for Prevymis is increasing, as it is an important drug treatment option for survival of high-risk patients.." Prevymis clinically demonstrated the inhibition of CMV reactivation and the reduction of mortality. Also, no adverse reactions related to myelotoxicity and nephrotoxicity occurred. Previmis is recommended as a prophylactic agent for allogeneic hematopoietic stem cell transplant patients with CMV seropositivity in the 2019 guidelines of the National Comprehensive Cancer Network (NCCN) and the European Conference on Infections on Leukemia (ECIL).
- Company
- Boycott Japan: Drug import rather increased in a year
- by Kim, Jin-Gu Jun 29, 2020 06:13am
- During a year of the Koreans boycotting against Japanese-made products, the total imported Japanese pharmaceutical sales have increased even more. But the trade balance has improved as the Korean-made pharmaceuticals exporting to Japan surged as well. Daily Pharm analyzed Korea Customs Service today and found the Japanese-made pharmaceutical import volume has increased by 2.1 percent from the time before the boycott. From the start of the boycott against Japanese product in June last year to May this year, the overall USD 390 million (approximately 469.6 billion won) of Japanese-made pharmaceuticals were imported in the year. Compared to the year before (June 2018 to May 2019), the figure jumped 2.1 percent (approximately 459.9 billion won) from 382 million dollars. The pharmaceutical import contrasts greatly against the overall Japanese product import volume plummeting by 11.8 percent from 51.54 billion dollars to 45.48 billion dollars. However, the trade balance has apparently improved with a steep increase in Korean-made pharmaceutical export to Japan. A year prior to the boycott, the export to Japan generated 193 million dollars, but during the year of boycott the figure leapt by 56.1 percent recording 310 million dollars. Due to the boycott, the trade deficit with Japan was dropped by about 100 million dollars from 189 million dollars to 89 million dollars. The change in pharmaceutical import and export with Japan from a year before (June 2018 to May 2019) and after (June 2019 to May 2020) the boycott against Japan. The Japanese-made pharmaceutical import rose (left) slightly, whereas the overall Japanese product import plunged by over 10% (Unit: USD 1 million) Source: Korea Customs Service The statistics show Korea has made trade surplus with Japan in January, April and May this year. For last two years, the pharmaceutical trading with Japan has never marked a monthly trade surplus. The pharmaceutical trade surplus with Japan generated 10 million dollars (exported 35 million dollars, imported 26 million dollars), 2 million dollars (exported 34 million dollars, imported 31 million dollars) and 3 million dollars (exported 24 million dollars and imported 21 million dollars) in January, April and May, respectively. The changes in trade balance with Japan in last two years. Korea made surplus in January, April and May this year (Unit: USD 1 million won) Source: Korea Customs Service The rare trade surplus aside, the Koreans boycotting against Japanese products does not seem to have brought a dire impact on the pharmaceutical sector. The monthly pharmaceutical import from Japan has been fluctuating from June to December last year, respectively marking 32 million dollars, 46 million dollars, 24 million dollars, 32 million dollars, 37 million dollars, 31 million dollars and 33 million dollars. The impact of boycotting was insignificant in pharmaceutical import this year as Korea imported 26 million dollars, 38 million dollars, 38 million dollars, 31 million dollars, and 21 million dollars of Japanese-made pharmaceuticals in January to May, respectively. Changes in Japanese pharmaceutical import from June 2018. Since June 2019 when the boycott movement started, the import volume fluctuated noticeably (Unit: USD 1 million) Source: Korea Customs Service The trend is also apparent in the outpatient prescription drug sales of top Japanese pharmaceutical companies in Korea until May. A pharmaceutical market research firm UBIST found Astellas Korea, Daiichi Sankyo Korea, Eisai Korea, Takeda Pharmaceutical Korea, Santen Pharmaceutical Korea and Korea Otsuka Pharmaceutical have generated total of 663.9 million won from outpatient sales within a year (June 2019 to May 2020). Compared to the outpatient drug sales performance in the year before (June 2018 to May 2019) at 662.7 million dollars, the figure only grew by 0.2 percent. Basically, the boycott has not affected the prescription drug sales. The change in prescription sales of Japanese pharmaceutical company product from a year before (June 2018 to May 2019) and after (June 2019 to May 2020) the boycott against Japan. Six companies did not demonstrate significant difference. (Unit: KRW 100 million) Source: UBIST The Koreans have revved up the boycott against Japanese products from June last year. When the Japanese government has reportedly decided to restrict the export of key material used in semi-conductor manufacturing, a large number of Korean consumers responded back by boycotting against Japanese-made beer, automobile, and consumer products. Regardless, the consumer boycott was unnoticeable in the pharmaceutical industry. The industry experts claim the boycott would have unlikely to target prescription drugs as they are, unlike OTC drugs, directly related to the people’s health. The majority of Japanese-made prescription drugs are original drugs with no alternative options used for highly severe diseases, which is why the switching drugs for the sake of boycotting would be unconvincing. In fact, Korean pharmacist groups have assertively participated in the boycott, but healthcare professionals did not openly join the movement.
- Company
- Dong-A ST is first to evade antidiabetic Forxiga patent
- by Lee, Tak-Sun Jun 29, 2020 06:13am
- For the first time in Korea, Dong-A ST has successfully evaded pharmaceutical patent on sodium-glucose co-transporter-2 (SGLT-2) inhibiting antidiabetic treatment Forxiga (dapagliflozin) by AstraZeneca. According to the pharmaceutical industry on June 25, Dong-A ST’s request for the negative scope confirmation on two Forxiga patents was accepted on June 23. The original drug has two substance patents to expire on Apr. 7, 2023 and Jan. 8, 2024, respectively. Following the legal proceeding, Dong-A ST would be the first company to knock on the follow-on dapagliflozin drug market. Dong-A ST is the only company that either evaded or nullified the original’s patent expiring on Apr. 7, 2023. The company would be able to launch a dapagliflozin product immediately after receiving the government’s approval. Other companies cannot launch a follow-on drug until Apr. 7, 2023 when the patent actually expires. The key to Dong-A ST’s patent evasion was modifying the original drug structure. For the patent-evaded dapagliflozin drug, the Korean company plans to conduct a Phase I trial and apply for item approval in the second quarter next year. If the product gets released next year, it would be two years earlier than other competitors. In the current antidiabetic treatment market dominated by DPP-4 inhibitor and SGLT-2 inhibitor, Dong-A ST would significantly expand its pie in the market with its independently developed new dipeptidyl peptidase 4 (DPP-4) inhibitor Suganon and the SGLT-2 inhibitor.
- Company
- New products join the already competitive bowel prep market
- by Lee, in-bok Jun 26, 2020 06:19am
- The bowel preparation market valued at 50 billion won is fluctuating noticeably. New products flooding in just a few years time have overly crowded the market. These products are jumping into the market with improved drug compliance for examinees and patients, but the market has not been easy for them to survive. Three types of bowel preparations approved in Korea In Korea, only three types of bowel preparations are approved by the health authority. Two types of polyethylene glycol (PEG) are most popular aside from oral sulfate solution (OSS). Iso-osmotic and non-absorbable PEG products are considered as the safest to use with lower risk of adverse change in electrolytes and metabolism. These are the reasons why Korea uses PEG the most. High-dose PEG, such as Colyte Powder and Colonlyte Powder, is usually supplied in 4 liter. Low-dose PEG, such as Coolprep Powder and Clicool Powder, is in 2-liter unit. Recently, many of PEG products are designed to be administered at minimum dose for better drug compliance. In fact, the majority of PEG products were in 4-liter unit when the U.S. Food and Drug Administration (FDA) first approved it in 1992, but now the market trend is leaning towards 2-liter dose after FDA approved the lower-dose product in 2006. OSS in tablet form was released to the market to enhance drug compliance with small amount. The world’s first incrementally modified OSS, Orafang by Pharmbio Korea is a well-known OSS tablet. While PEG still dominates the market, Orafang struggles to settle down Currently, Taejoon Pharmaceutical owns the biggest pie in the bowel prep market. The company generates over 10 billion won, easily topping the market valued at 50 billion won. In 1990s, Taejoon Pharmaceutical imported Colyte Powder and Colyte F Powder, and continued to dominate the market over a decade with FDA-approved Coolprep and other various doses of PEGs. The Korean company has the fullest line up in the market. Joining the race late, Pharmbio Korea seems to have avoided PEG by launching the world’s first incrementally modified OSS Orafang in May last year. To snatch a chance to compete in the bowel prep market, the company had to find a key product besides PEG. Pharmbio actually has tried the market with PEG before, but the performance was underwhelming. Although it was dropped during clinical stage in 2013 due to unforeseen renal issues, the conveniently administered Orafang came back in tablet form with most of the problematic part sorted out. Phase III trials conducted in eight hospitals like Seoul National University Hospital and Korea University Medical Center have confirmed Orafang’s bowel cleansing efficacy at 95.5 percent non-inferior against other OSS in liquid form at 98.2 percent. But apparently, the OSS was faced with limitation in the PEG-dominated market. The biggest difficulty was entering university hospitals. A head of general medical checkup center at one of Big Five hospitals hinted, “We are aware of Orafang, but the hospital does not use it or have a plan to consider using,” and “checking at conferences and seminars, majority of university hospitals were not interested in entering the product’s prescription code.” New products flooding in, the latecomer competition also unavoidable Regardless of the world’s first incrementally modified drug struggling to expand in the market, new products are released one after another in the Korean bowel prep market. The latecomers’ competition would inevitably heat up high as the market is already crowded with firstcomers. Korea Pharma has signed an exclusive deal with Norgine, a Dutch company specializing in bowel prep, for supplying PLENVU in the Korean market. Kolmar Korea is readying for the launch of Easyprep 1.38 Power that reduced the regimen amount down to 1.38 liter. The company has received Ministry of Food and Drug Safety’s (MFDS) approval on the incrementally modified drug. Dong Seok Ho, a President of the Korean Society of Health Screening and Promotion, stated “The board of directors is also reviewing newly released bowel preps through product presentation,” but “as all of them have clear advantages and differentiate themselves by improved drug compliance, products with high level of safety and bowel cleansing efficacy would ultimately win the market.”
- Company
- Pharmacist's No. 1 product among athlete's foot tx, Tiersil
- by Lee, Seok-Jun Jun 25, 2020 07:02am
- The pharmacist's recommendation for 'once-form athlete's foot treatment' was found to be due to patient convenience (40.4%), medication compliance, and therapeutic effect (39.9%). The pharmacist's No. 1 product among athlete's foot fungus drugs was investigated as 'Tiersil Once (Terbinafine Hydrochloride)’. Dailypharm conducted an online survey of 1,970 pharmacists on the 10th of this month to understand the current status of over-the-counter medications for athlete's foot. Athlete's foot is a disease that occurs well in summer. According to the results of the survey, 99% of pharmacists analyzed that they were primarily recommending 'Terbinafine' when administering athlete's foot medicine. 'Terbinafine' is known to have a fast and excellent treatment effect against dermatophyte, the main cause of athlete's foot, compared to 'Clotrimazole', an extensive antifungal agent. The reason that athlete's foot treatment was not properly treated with athlete's foot treatment was that 53.1% of the patients judged that they had improved themselves and stopped. Next, it was followed by 'because the treatment for athlete's foot that needs to be applied daily is uncomfortable and annoying (22.2%)', and the treatment period is too long (16.9%)'. Discomfort is the biggest reason. The actual once formulation does not have the hassle to apply daily, such as a cream or gel, as the drug continuously penetrates for up to about 2 weeks when applied once. In particular, it has the advantage of being effective because it is possible to forcefully treat athlete's foot to the end. However, pharmacists ranked the preferred athlete's foot treatment formulations as cream (48.2%), gel (41.1%), and once (5.8%). The advantage of Once is clear, but 'Cream' type is the most well-known formulation because it is familiar to patients, and 'Gel'type is the second because of patient’s compliance. Among the once formulations, the pharmacist's preference was ranked 1st at Tier Silence (41.6%) and 2nd at Lamisil Once (35.7%). It also works with figures. According to 1Q IMS data in 2020, Tiersil Once was ranked 49.1% in the market of 'Once', surpassing 'Lamisil once' and ranked first in the market share. Sales grew 961.4% YoY. The key to the popularity of Tiersil Once is the convenience and effectiveness of the once-in-the-box formulation, as well as 'high margin rate (44.4%) in pharmacies', 'brand and product awareness (27.5%)', and 'high repurchase rate (10.6%)'. Some suggested that using Trot star Song Ga-in as a model increased awareness. Tiersil Once used a 'silicone film' that has excellent drug treatment and a high raw material cost compared to other raw materials because its drug delivery power is up to 3 times higher. Although the cost of the product is high and it is an advertising product, it is evaluated to coexist with pharmacies because it does not lower the margin rate. There was also an opinion on combination therapy. 94% of pharmacists recommended two or more formulations for effective athlete's foot treatment. 'Combination therapy' mainly used a combination of a product (cream, gel, once) and a product to spray (spray, aerosol). There was also a response that containing the 'once' formulation that treats athlete's foot with a single application and 'Lidocaine', which can quickly relieve itching, can conveniently maximize the therapeutic effect by using athlete's foot medicine in combination. Athlete's foot types are divided into interstitial, angular, and blister types. 'Tiersil Once' can be applied to all athlete's foot except for chronic keratinized athlete's foot. In addition to Once, there is also 'Tiersil Aerosol' in the Tiersil athlete's foot lineup.
- Company
- Hanmi Science Presents 6 Great Visions for Post COVID-19
- by dailypharm Jun 25, 2020 06:09am
- Hanmi Science with the gene of 'Innovation' presented six great visions for the post COVID-19. Hanmi Science's 6 visions, abbreviated as 'Cydio Cigma', imply key words as 'Cyber Education','Digital Bio','Oral Bio','City Bio','Green Bio', and 'Marine Bio'. For the vision business, CEO Chong-Yoon Lim promised to raise outstanding employees’ annual salary by 100% regardless of the ranks. “Where there is no innovation, there is no development! Those who shrink from challenges are branded as cowards ! The cyber education business, digital bio business, oral bio business, city bio business, green bio business, marine bio business, and Cydio Cigma are our goals and commitments for the post-COVID-19. ” These are the 6 great visions of Hanmi Science unveiled at the 'Tea Time' executive meeting, which is also the tradition of Hanmi, on the 15th at 7:30 am. The road map of the post-pandemic era was presented. Hanmi Pharmaceutical Group has always been recognized as an innovative company in Korean pharmaceutical bio industry. Through the equation "Hanmi = R&D", it has become a classic example of innovation in the pharmaceutical and biological industries, as well as a symbol of the company that represents the development of new drugs. Now, the case of Hanmi's innovation and R&D has gone beyond the development of new drugs, and deviated from the framework of all existing industries, drawing a blueprint on a blank sheet of paper. With the mission of combating the post-COVID-19 era, Hanmi, as a leader of K-Bio, has formulated six visions with Hanmi's macroscopic future pharmaceutical, bio, and health and welfare solution strategies. Hanmi Science's 6 great visions, abbreviated as 'Cydio Cigma', imply key words as 'Cyber Education','Digital Bio','Oral Bio','City Bio','Green Bio', and 'Marine Bio'. Each item for the six businesses is Cyber Education, Digital Bio, Oral Bio, City Bio, Green Bio, and Marine Bio. On this day, CEO Chong-Yoon Lim promised to change the existing HR resources system by offering 100% annual salary increases and job titles to those who deliver concrete performance related to those 6 great visions Goal & Promise, is a personnel management system for actualizing management goals of Hanmi, and publicly proposed to discover talents inside the company that transcend positions to perform and participate in the 6 vision projects. Hanmi Pharmaceutical Group (hereinafter referred to as Hanmi) officially declared its macroscopic goals, changes and wills in order to cope with the post-COVID-19 era. Launched “Cyber Industry-University Cooperation Academy” in cooperation with global leading bio-medical universities Looking specifically at the six visions proposed this time, first of all, the framework of "Cyber Education" is the establishment of K-Bio and K-Med graduate schools, attracting more than 5,000 foreign experts. Hanmi Science Group has been accumulating cooperation and joint research courses with overseas medical, bio-related universities and research institutes over the past few years. It was not a temporary solution, but rather it’s in line with the most important policy of R&D in Hanmi Pharmaceutical Group. Starting with a joint research agreement for public health in Korea-Italy with Catholic Medical School in Rome, Italy and the Policlinico Universitario Agostino Gemelli in late 2017, CEO Chong-Yoon Lim established a global research network based on joint research for low birth rates, neonatal health and postpartum care and other common problems between Korea and Italy. Cooperating with Beijing Union Medical School, which participated as a consortium, he has expanded the concept to fit China, and is conducting research to suit the characteristics of Korea, China, and Italy by adding in-depth research on the need for advanced maternal and child health and the possibility to improve the efficiency of social health economy through pregnancy management in a country with 20 million newborn babies. Hanmi defines Digital Bio The following is about "Digital Bio", one of the 6 great visions. Hanmi Science is promoting the 4th medical industry revolution by combining information and communication technology and big data through continuous investment in research and development capabilities. Hanmi Science launches Paltan Smart Plant equipped with a cutting-edge technology and unveils the next-generation innovative medical infrastructure system based on the know-how of Hanmi's electronic distribution network management system, unmanned prescription system, and hospital information system over the past 20 years. Hanmi is not a base for electronics, portals, or online distribution, but is a specialized bio-medical group that has been conducting more than 500 drug developments and clinical trials of more than 30 new bio drugs over 50 years. Currently, various organizations, including the Ministry of Health and Welfare and the U.S. FDA, recognize the importance of participating in such innovative medical systems with verified professional companies. In addition to chronic disease and pregnancy health care, Hanmi is applying for a number of global patents for medical software to cure COVID-19 and is working with the National Institute of Health and Welfare to develop a system that will be applied to the site. Since it can be applied simultaneously in cooperation hospitals in China and Italy, it is expected that such efforts will lead to the positive results of the K quarantine. Leading the Oral Bio new drug business, Most domestic new biologics are still injectables. However, Hanmi, which has developed more than 400 oral medicines, as a leader in the healthcare/medicine market in the post-COVID-19 era, has the world's best technology in oral treatment development. This is a completely differentiating strategy from existing major bio companies based on large biosimilar (biopharmaceutical generics) factories. In particular, among the factories owned by Hanmi, Paltan Smart Factory is the world's best smart factory capable of producing 6 billion tablets annually and 90% unmanned processes. In addition, Oraxol, which applied the patent platform technology 'Orascovery', transferred technology to Athenex, a US biopharmaceutical company in 2011, recently announced cases of complete recovery from the most difficult groups of patients to treat at ASCO, as a result of the recent third-phase global clinical trial. Seeing the post-COVID-19 era as a innovative breakthrough and opportunity, Hanmi unveiled a blueprint for the next generation of Orascovery. Currently, about 800 new COVID-19 related drugs are being developed around the world, but new drugs developed as oral or non-injection drugs are rarely found. It is also considered the most reckless attempt. But worth it. The biggest problem under the pandemic situation is the shortage of medical staff including nursing personnel, the lack of medical facilities, and the time from treatment development to commercialization. As an influential treatment for COVID-19 that can overcome these difficulties, we develop an oral (non-injection) vaccine containing the next-generation Orascovery technology. "We have already experienced countless failures and overcomes. In response to the challenge faced by human beings called Pandemic, Hanmi will start preclinical trials of "COVID MDT", the safest and most effective treatment by integrating accumulated technology and innovative treatment models. There is no more failure than fear of not challenging," he expressed with confidence. Signed MOU 'City Bio' with Gyeongsangbuk-do, Pohang-si and Daegu-Gyeongbuk Free Economic Zone Authority Hanmi Science leads the creation of Smart Health care City. Hanmi Science and the Gyeongsangbuk-do, Pohang-si, and Daegu-Gyeongbuk Free Economic Zone Authority signed an MOU for biomedical smart city with a business size of about 300 billion won including education, R&D and manufacturing facilities in Pohang Convergence Technology Industrial Zone on the 15th. Smart Eco City, which will be unfolded on a green area of 15,000 square meters, is a prototype city that manages life quality from birth to daily life through a pollution-free bio-environment for all cities and citizens with "administrative regional medical resource management" suitable for the post-COVID-19 era. The computing center, which corresponds to the brain of this smart city, is a kind of cloud-based solution similar to a large ERP system designed to enable real-time continuous analysis of biological activity in the region, citizen health care, medical resource management, knowledge data base, world-class education, quality of life including food, exercise, culture, and medical institutionalization of all urban facilities in case of emergency. In addition, it is equipped with educational facilities capable of real-time linking to advanced overseas research institutes, so it is possible to respond to joint research by sharing bio-bank data in medical and medical situations of world-class medical staff if necessary. As a post-COVID-19 vision business called City Bio, it will be built as a 'Future City' that combines the 50-year know-how of the global Hanmi. Green Bio, applying plant biotechnology, expanding global healthcare group Hanmi Science signed a strategic business agreement with BioApp, a promising venture company in the field of plant biotechnology in Korea, and promised joint development and joint marketing of plant-based bio products, also known as "green vaccines," for domestic and international markets. In particular, the two companies announced that they will collaborate on the development and commercialization of green vaccines against various diseases including COVID-19, which is a recent issue. In addition, the two companies agreed to establish a joint venture for the overseas sales of the world's first plant-based swine fever marker vaccine product that has been developed and commercialized by BioApps, and announced that they would select China as the first market and proceed with joint venture establishment and product registration in the near future. This model has received a great deal of attention from the industry because it is a collaboration between the outstanding technology of domestic bio companies and Hanmi Science's “Open Innovation” method, which has already pioneered overseas markets. The two companies are ultimately drawing a blueprint to challenge Human Madison based on plant biotechnology. Hanmi Science signed a technology transfer contract with Duhu Liu, a professor at the Chinese Academy of Agricultural Sciences, for a new drug candidate related to metabolic disease, and started developing a new green bio drug. In order to sign a vision business contract with China's top bio-biotechnology organization, CEO Chong-Yoon Lim visited China more than three times to discuss marketability for related technologies and discuss development roadmaps with the Chinese Academy of Agricultural Sciences. Through this agreement, Hanmi Science and the Chinese Academy of Agricultural Sciences announced that they will jointly complete the preclinical studies necessary for clinical trials of new drug candidates, and to work closely with the Beijing Hanmi Research Institute in the clinical process. According to Hanmi Science officials, in addition to the candidate materials, it was emphasized that a review of the application of plant and biotechnology to blockbuster-class pipelines also began inside the company. Now, Hanmi Science has joined forces with researchers who has the best green bio technology in both Korea and China to realize the fifth vision of the post-COVID-19 era to "Revolutionize" the huge production and research costs of existing bio-new drugs development. Marine Bio,Open a convergence Marine Bio Center in Pohang Penta City Hanmi is looking for a future vision business in the 'Ocean', which is the original birthplace of living thins on the Earth, and a bio-bank of all living creatures that preserve the evolutionary process and covers 70% of the Earth's surface. In other words, Hanmi Science threw a vote in an unfamiliar area called Marine Bio. This is a vision project for understanding, protecting, preserving of marine bio resources,where 80% of the world's species are inhabited but commercial utilization is less than 1% and researching new drug development mechanisms and deriving lead materials. In 2004, the pain reliever Prialt, which was created using the toxicity of sea snails, was reported to have generated $27 million in sales in 2017, while the black beach sponges-based anti-cancer drug, developed in Japan and approved FDA in 2010, generated $3.6 billion worldwide in 2017. With the marine bio industry expected to grow into a market worth about $8.05 billion by 2030, given the domestic situation focused on the aquatic food processing industry, Hanmi Science's Marine Bio Vision business is a roadmap to bring Korea back into the ocean power. In particular, Pohang is the best place to have the best conditions for the location of marine resources, with the long history of proving it, and the fourth generation of accelerators. Through marine bio research, it is possible to study the underlying biological mechanisms by studying genomic studies before and after evolution, understanding of the inter-microbial ecosystem of viruses, and the origin of human cell functions. Hanmi's Marine Bio Center is expected to be the Noah's Ark of the marine life system. In regards to Korean NIH's announcement on April about discovering potential COVID-19 vaccine using VLP(virus like particle), Hanmi Science and the authority are seriously considering possible measures to co-develop the candidate.
